Drug intelligence / Profile preview

999 Ganmaoling

Development stage
Unknown
Lead developer
China Resources Sanjiu Medical & Pharmaceutical
Modality
Small Molecules
Administration
Oral
01

Overview

999 Ganmaoling is a widely recognized over-the-counter (OTC) hybrid medication developed and marketed by CR Sanjiu for the symptomatic relief of the common cold and upper respiratory tract infections. The product is a 'hybrid' formulation, integrating Western pharmaceutical compounds—specifically acetaminophen (0.2g), caffeine (4mg), and chlorpheniramine maleate (4mg)—with a blend of traditional Chinese medicinal herbs including *Evodia lepta*, *Ilex asprella*, wild chrysanthemum, *Bidens pilosa*, and peppermint oil. This combination provides comprehensive relief from fever, headache, sore throat, nasal congestion, and runny nose. It is formulated as granules for oral administration, typically dissolved in hot water, and holds a formal drug approval in China (国药准字Z44021940).

Brand names
999感冒灵999 GanmaolingSanjiu Ganmaoling999 Cold Remedy
Other names
三九感冒灵
02

Targets

ADORA1 (Adenosine receptor A1 subtype)ADORA2A (Adenosine A₂A Receptor)HRH1 (Histamine H1 Receptor)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on 999 Ganmaoling.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 999 Ganmaoling.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call